All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During ASCO and EHA 2021, the MPN Hub spoke with Ruben A Mesa, UT Health San Antonio, San Antonio, US. We asked, How does transfusion independence impact survival outcomes with momelotinib in myelofibrosis (MF)?
How does transfusion independence impact survival outcomes with momelotinib in MF?
Momelotinib is a JAKi that attenuates anemia in patients with MF. Mesa describes an analysis of the SIMPLIFY-1 study, comparing momelotinib with ruxolitinib in the frontline setting, and presents the correlation between transfusion-independent response and overall survival (OS) with momelotinib treatment.
Use of integrative medicine may correlate with improved symptoms and quality of life in patients with MPN
Myeloproliferative neoplasms (MPN) are associated with a high symptom burden and the risk of progression to acute myeloid leukemia (AML)....
SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment in R/R MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We...
Subscribe to get the best content related to MPN delivered to your inbox